Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in Patients with Psoriatic Arthritis (PsA)

 Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in Patients with Psoriatic Arthritis (PsA)

Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in Patients with Psoriatic Arthritis (PsA)

Shots:

  • The label update includes dosing flexibility of Cosentyx up to 300 mg based on clinical response & SC structural data of 24 wks., showing inhibition in progression of joint damage in PsA
  • Cosentyx label update is based on safety and efficacy of 300mg in follow-up titration & results from P-III FUTURE 5 study (N=996) @24 wks. showing results of no radiographic disease progression in 90% of patients
  • Cosentyx is novel inhibitor for IL-17A in PsA & AS, prescribed to 160,000 patients WW. The updated label is applicable in EU including all EEA countries

Click here to read full press release/ article | Ref: Novartis | Image: Phys

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post